Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma

Gaurav Verma, Sanjeev Chawla, Suyash Mohan, Sumei Wang, MacLean Nasrallah, Sulaiman Sheriff, Arati Desai, Steven Brem, Donald M. O'Rourke, Ronald L. Wolf, Andrew A Maudsley, Harish Poptani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Accurate differentiation of true progression (TP) from pseudoprogression (PsP) in patients with glioblastomas (GBMs) is essential for planning adequate treatment and for estimating clinical outcome measures and future prognosis. The purpose of this study was to investigate the utility of three-dimensional echo planar spectroscopic imaging (3D-EPSI) in distinguishing TP from PsP in GBM patients. For this institutional review board approved and HIPAA compliant retrospective study, 27 patients with GBM demonstrating enhancing lesions within six months of completion of concurrent chemo-radiation therapy were included. Of these, 18 were subsequently classified as TP and 9 as PsP based on histological features or follow-up MRI studies. Parametric maps of choline/creatine (Cho/Cr) and choline/N-acetylaspartate (Cho/NAA) were computed and co-registered with post-contrast T1-weighted and FLAIR images. All lesions were segmented into contrast enhancing (CER), immediate peritumoral (IPR), and distal peritumoral (DPR) regions. For each region, Cho/Cr and Cho/NAA ratios were normalized to corresponding metabolite ratios from contralateral normal parenchyma and compared between TP and PsP groups. Logistic regression analyses were performed to obtain the best model to distinguish TP from PsP. Significantly higher Cho/NAA was observed from CER (2.69 ± 1.00 versus 1.56 ± 0.51, p = 0.003), IPR (2.31 ± 0.92 versus 1.53 ± 0.56, p = 0.030), and DPR (1.80 ± 0.68 versus 1.19 ± 0.28, p = 0.035) regions in TP patients compared with those with PsP. Additionally, significantly elevated Cho/Cr (1.74 ± 0.44 versus 1.34 ± 0.26, p = 0.023) from CER was observed in TP compared with PsP. When these parameters were incorporated in multivariate regression analyses, a discriminatory model with a sensitivity of 94% and a specificity of 87% was observed in distinguishing TP from PsP. These results indicate the utility of 3D-EPSI in differentiating TP from PsP with high sensitivity and specificity.

Original languageEnglish (US)
Article numbere4042
JournalNMR in Biomedicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Echo-Planar Imaging
Glioblastoma
Choline
Imaging techniques
Creatine
Regression Analysis
Health Insurance Portability and Accountability Act
Research Ethics Committees
Radiotherapy
Metabolites
Magnetic resonance imaging
Logistics
Multivariate Analysis
Retrospective Studies
Logistic Models
Outcome Assessment (Health Care)
Planning
Sensitivity and Specificity
N-acetylaspartate

Keywords

  • echo planar spectroscopic imaging
  • glioblastoma
  • proton MRS
  • pseudoprogression
  • true progression
  • tumor treatment response

ASJC Scopus subject areas

  • Molecular Medicine
  • Radiology Nuclear Medicine and imaging
  • Spectroscopy

Cite this

Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. / Verma, Gaurav; Chawla, Sanjeev; Mohan, Suyash; Wang, Sumei; Nasrallah, MacLean; Sheriff, Sulaiman; Desai, Arati; Brem, Steven; O'Rourke, Donald M.; Wolf, Ronald L.; Maudsley, Andrew A; Poptani, Harish.

In: NMR in Biomedicine, 01.01.2018.

Research output: Contribution to journalArticle

Verma, Gaurav ; Chawla, Sanjeev ; Mohan, Suyash ; Wang, Sumei ; Nasrallah, MacLean ; Sheriff, Sulaiman ; Desai, Arati ; Brem, Steven ; O'Rourke, Donald M. ; Wolf, Ronald L. ; Maudsley, Andrew A ; Poptani, Harish. / Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma. In: NMR in Biomedicine. 2018.
@article{a1cd3669dd394bee8a2ec7407564ea8b,
title = "Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma",
abstract = "Accurate differentiation of true progression (TP) from pseudoprogression (PsP) in patients with glioblastomas (GBMs) is essential for planning adequate treatment and for estimating clinical outcome measures and future prognosis. The purpose of this study was to investigate the utility of three-dimensional echo planar spectroscopic imaging (3D-EPSI) in distinguishing TP from PsP in GBM patients. For this institutional review board approved and HIPAA compliant retrospective study, 27 patients with GBM demonstrating enhancing lesions within six months of completion of concurrent chemo-radiation therapy were included. Of these, 18 were subsequently classified as TP and 9 as PsP based on histological features or follow-up MRI studies. Parametric maps of choline/creatine (Cho/Cr) and choline/N-acetylaspartate (Cho/NAA) were computed and co-registered with post-contrast T1-weighted and FLAIR images. All lesions were segmented into contrast enhancing (CER), immediate peritumoral (IPR), and distal peritumoral (DPR) regions. For each region, Cho/Cr and Cho/NAA ratios were normalized to corresponding metabolite ratios from contralateral normal parenchyma and compared between TP and PsP groups. Logistic regression analyses were performed to obtain the best model to distinguish TP from PsP. Significantly higher Cho/NAA was observed from CER (2.69 ± 1.00 versus 1.56 ± 0.51, p = 0.003), IPR (2.31 ± 0.92 versus 1.53 ± 0.56, p = 0.030), and DPR (1.80 ± 0.68 versus 1.19 ± 0.28, p = 0.035) regions in TP patients compared with those with PsP. Additionally, significantly elevated Cho/Cr (1.74 ± 0.44 versus 1.34 ± 0.26, p = 0.023) from CER was observed in TP compared with PsP. When these parameters were incorporated in multivariate regression analyses, a discriminatory model with a sensitivity of 94{\%} and a specificity of 87{\%} was observed in distinguishing TP from PsP. These results indicate the utility of 3D-EPSI in differentiating TP from PsP with high sensitivity and specificity.",
keywords = "echo planar spectroscopic imaging, glioblastoma, proton MRS, pseudoprogression, true progression, tumor treatment response",
author = "Gaurav Verma and Sanjeev Chawla and Suyash Mohan and Sumei Wang and MacLean Nasrallah and Sulaiman Sheriff and Arati Desai and Steven Brem and O'Rourke, {Donald M.} and Wolf, {Ronald L.} and Maudsley, {Andrew A} and Harish Poptani",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/nbm.4042",
language = "English (US)",
journal = "NMR in Biomedicine",
issn = "0952-3480",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Three-dimensional echo planar spectroscopic imaging for differentiation of true progression from pseudoprogression in patients with glioblastoma

AU - Verma, Gaurav

AU - Chawla, Sanjeev

AU - Mohan, Suyash

AU - Wang, Sumei

AU - Nasrallah, MacLean

AU - Sheriff, Sulaiman

AU - Desai, Arati

AU - Brem, Steven

AU - O'Rourke, Donald M.

AU - Wolf, Ronald L.

AU - Maudsley, Andrew A

AU - Poptani, Harish

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Accurate differentiation of true progression (TP) from pseudoprogression (PsP) in patients with glioblastomas (GBMs) is essential for planning adequate treatment and for estimating clinical outcome measures and future prognosis. The purpose of this study was to investigate the utility of three-dimensional echo planar spectroscopic imaging (3D-EPSI) in distinguishing TP from PsP in GBM patients. For this institutional review board approved and HIPAA compliant retrospective study, 27 patients with GBM demonstrating enhancing lesions within six months of completion of concurrent chemo-radiation therapy were included. Of these, 18 were subsequently classified as TP and 9 as PsP based on histological features or follow-up MRI studies. Parametric maps of choline/creatine (Cho/Cr) and choline/N-acetylaspartate (Cho/NAA) were computed and co-registered with post-contrast T1-weighted and FLAIR images. All lesions were segmented into contrast enhancing (CER), immediate peritumoral (IPR), and distal peritumoral (DPR) regions. For each region, Cho/Cr and Cho/NAA ratios were normalized to corresponding metabolite ratios from contralateral normal parenchyma and compared between TP and PsP groups. Logistic regression analyses were performed to obtain the best model to distinguish TP from PsP. Significantly higher Cho/NAA was observed from CER (2.69 ± 1.00 versus 1.56 ± 0.51, p = 0.003), IPR (2.31 ± 0.92 versus 1.53 ± 0.56, p = 0.030), and DPR (1.80 ± 0.68 versus 1.19 ± 0.28, p = 0.035) regions in TP patients compared with those with PsP. Additionally, significantly elevated Cho/Cr (1.74 ± 0.44 versus 1.34 ± 0.26, p = 0.023) from CER was observed in TP compared with PsP. When these parameters were incorporated in multivariate regression analyses, a discriminatory model with a sensitivity of 94% and a specificity of 87% was observed in distinguishing TP from PsP. These results indicate the utility of 3D-EPSI in differentiating TP from PsP with high sensitivity and specificity.

AB - Accurate differentiation of true progression (TP) from pseudoprogression (PsP) in patients with glioblastomas (GBMs) is essential for planning adequate treatment and for estimating clinical outcome measures and future prognosis. The purpose of this study was to investigate the utility of three-dimensional echo planar spectroscopic imaging (3D-EPSI) in distinguishing TP from PsP in GBM patients. For this institutional review board approved and HIPAA compliant retrospective study, 27 patients with GBM demonstrating enhancing lesions within six months of completion of concurrent chemo-radiation therapy were included. Of these, 18 were subsequently classified as TP and 9 as PsP based on histological features or follow-up MRI studies. Parametric maps of choline/creatine (Cho/Cr) and choline/N-acetylaspartate (Cho/NAA) were computed and co-registered with post-contrast T1-weighted and FLAIR images. All lesions were segmented into contrast enhancing (CER), immediate peritumoral (IPR), and distal peritumoral (DPR) regions. For each region, Cho/Cr and Cho/NAA ratios were normalized to corresponding metabolite ratios from contralateral normal parenchyma and compared between TP and PsP groups. Logistic regression analyses were performed to obtain the best model to distinguish TP from PsP. Significantly higher Cho/NAA was observed from CER (2.69 ± 1.00 versus 1.56 ± 0.51, p = 0.003), IPR (2.31 ± 0.92 versus 1.53 ± 0.56, p = 0.030), and DPR (1.80 ± 0.68 versus 1.19 ± 0.28, p = 0.035) regions in TP patients compared with those with PsP. Additionally, significantly elevated Cho/Cr (1.74 ± 0.44 versus 1.34 ± 0.26, p = 0.023) from CER was observed in TP compared with PsP. When these parameters were incorporated in multivariate regression analyses, a discriminatory model with a sensitivity of 94% and a specificity of 87% was observed in distinguishing TP from PsP. These results indicate the utility of 3D-EPSI in differentiating TP from PsP with high sensitivity and specificity.

KW - echo planar spectroscopic imaging

KW - glioblastoma

KW - proton MRS

KW - pseudoprogression

KW - true progression

KW - tumor treatment response

UR - http://www.scopus.com/inward/record.url?scp=85058688192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058688192&partnerID=8YFLogxK

U2 - 10.1002/nbm.4042

DO - 10.1002/nbm.4042

M3 - Article

C2 - 30556932

AN - SCOPUS:85058688192

JO - NMR in Biomedicine

JF - NMR in Biomedicine

SN - 0952-3480

M1 - e4042

ER -